diallyl trisulfide has been researched along with Lymphoma, Primary Effusion in 1 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Fujimuro, M; Furukawa, Y; Hosokawa, K; Kagawa, H; Matsuhiro, J; Minami, S; Nakagawa, K; Nakata, S; Shigemi, Z; Takeda, H; Watanabe, T | 1 |
1 other study(ies) available for diallyl trisulfide and Lymphoma, Primary Effusion
Article | Year |
---|---|
Diallyl trisulfide induces apoptosis by suppressing NF-κB signaling through destabilization of TRAF6 in primary effusion lymphoma.
Topics: Allyl Compounds; Animals; Apoptosis; Cell Line, Tumor; Humans; I-kappa B Kinase; I-kappa B Proteins; Intracellular Signaling Peptides and Proteins; Lymphoma, Primary Effusion; Mice; Neoplasm Proteins; NF-kappa B; NF-KappaB Inhibitor alpha; Nitriles; Phosphorylation; Proteolysis; Signal Transduction; Sulfides; Sulfones; Xenograft Model Antitumor Assays | 2016 |